Century Therapeutics, Inc. (IPSC)
Century Therapeutics, Inc. (IPSC) is a healthcare company (biotechnology) based in the United States. The share price is $1.46, down 10.98% on the day, which values the company at $265.13M. Price as of 17 Nov 2026, 17:31 UTC, from Yahoo Finance.
Key facts
- Share price
- $1.46−10.98% today
- Market value
- $265.13M
- Funk Score
- 50/100
- Against its own history
- Well below its usual priceusual price $22.47
- 200-week average
- $2.0428% below
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Century Therapeutics, Inc. in more detail
IPSC trades at -3.3× next year's expected earnings. Measured against its own history, the price is 94% below what its usual multiples would imply ($22.47) — well below its usual price. It sits 28% below its 200-week average of $2.04.
Its Funk Score is 50 out of 100 (financial strength 4.6, profitability 2.0, growth 8.3, value 5.0, each out of 10).
In its favour: More cash than debt. Worth checking: Altman Z in the distress zone; Weak Piotroski score.
1 of the superinvestors tracked here hold IPSC, including Peter Kolchinsky (0.4% of the portfolio).
Superinvestors holding IPSC
1 of the investors tracked here report a position in their latest 13F filing.
- Peter Kolchinsky RA Capital Management0.38% of portfolio · $43.5M · Q2 2026
Century Therapeutics, Inc. (IPSC): questions and answers
What is Century Therapeutics, Inc.'s market cap?
Century Therapeutics, Inc. is valued at $265.13M at a share price of $1.46.
Is IPSC overvalued or undervalued?
Against its own history, IPSC is well below its usual price: the price is 94% below the $22.47 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.
Is IPSC above its 200-week moving average?
No. IPSC is 28.4% below its 200-week average of $2.04. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Century Therapeutics, Inc. growing?
Over the last three fiscal years Century Therapeutics, Inc.'s revenue grew 175.9% a year.
Does IPSC pay a dividend?
Century Therapeutics, Inc. does not currently pay a regular dividend.
Which famous investors own IPSC?
In their latest quarterly filings, Peter Kolchinsky (0.4% of the portfolio) hold IPSC. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Century Therapeutics, Inc. (IPSC) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/IPSC
Underlying data: Yahoo Finance; company filings with the SEC.